| Autor: |
Kerényi, Adrienne, Beke Debreceni, Ildikó, Oláh, Zsolt, Ilonczai, Péter, Bereczky, Zsuzsanna, Nagy, Béla, Muszbek, László, Kappelmayer, János |
| Zdroj: |
Cytometry Part B: Clinical Cytometry; September 2017, Vol. 92 Issue: 5 p389-397, 9p |
| Abstrakt: |
Heparin‐induced thrombocytopenia (HIT) is a severe side effect of heparin treatment caused by platelet activating IgG antibodies generated against the platelet factor 4 (PF4)–heparin complex. Thrombocytopenia and thrombosis are the leading clinical symptoms of HIT. The clinical pretest probability of HIT was evaluated by the 4T score system. Laboratory testing of HIT was performed by immunological detection of antibodies against PF4–heparin complex (EIA) and two functional assays. Heparin‐dependent activation of donor platelets by patient plasma was detected by flow cytometry. Increased binding of Annexin‐V to platelets and elevated number of platelet‐derived microparticles (PMP) were the indicators of platelet activation. EIA for IgG isotype HIT antibodies was performed in 405 suspected HIT patients. Based on negative EIA results, HIT was excluded in 365 (90%) of cases. In 40 patients with positive EIA test result functional tests were performed. Platelet activating antibodies were detected in 17 cases by Annexin V binding. PMP count analysis provided nearly identical results. The probability of a positive flow cytometric assay result was higher in patients with elevated antibody titer. 71% of patients with positive EIA and functional assay had thrombosis. EIA is an important first line laboratory test in the diagnosis of HIT; however, HIT must be confirmed by a functional test. Annexin V binding and PMP assays using flow cytometry are functional HIT tests convenient in a clinical diagnostic laboratory. The positive results of functional assays may predict the onset of thrombosis. © 2016 International Clinical Cytometry Society |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text